Detalhe da pesquisa
1.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer
; 154(9): 1607-1615, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38196128
2.
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
Jpn J Clin Oncol
; 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38594880
3.
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L).
BMC Cancer
; 23(1): 902, 2023 Sep 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37749521
4.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Int J Clin Oncol
; 28(1): 79-88, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36414827
5.
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Int J Clin Oncol
; 28(1): 69-78, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36357710
6.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1354-1368, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37548831
7.
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Oncologist
; 27(9): 720-e702, 2022 09 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35759340
8.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Invest New Drugs
; 40(2): 361-369, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35088212
9.
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol
; 27(12): 1828-1838, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36036294
10.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Oncologist
; 26(1): 19-e52, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32918791
11.
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
BMC Cancer
; 21(1): 346, 2021 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33794809
12.
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.
Support Care Cancer
; 29(9): 5237-5244, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-33649919
13.
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer
; 126(9): 1940-1948, 2020 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32022929
14.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Invest New Drugs
; 38(1): 211-218, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31784866
15.
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
BMC Cancer
; 20(1): 93, 2020 Feb 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32013910
16.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Oncologist
; 24(5): 593-e170, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30651400
17.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Invest New Drugs
; 37(6): 1266-1273, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31392549
18.
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Oncology
; 97(6): 327-333, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31412347
19.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Cancer
; 124(19): 3830-3838, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30192383
20.
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol
; 28(5): 724-725, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36648711